CD8A and neoplasm: Inhibitors of immune checkpoint modulators such as programmed death 1 (PD‐1) and cytotoxic T‐lymphocyte antigen 4 (CTLA‐4) invigorate CD8+ T cell‐mediated killing of tumor cells and are revolutionizing immunotherapy of cancer.